Dose considerations for anti-cancer drugs in metastatic prostate cancer

Megan Crumbaker, Howard Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.

LanguageEnglish
Pages1199-1204
Number of pages6
JournalProstate
Volume77
Issue number11
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

docetaxel
Prostatic Neoplasms
Pharmaceutical Preparations
Neoplasms
Quality of Life
Therapeutics
MDV 3100
Abiraterone Acetate
cabazitaxel

Keywords

  • dosing
  • prostate cancer
  • treatment

Cite this

Crumbaker, Megan ; Gurney, Howard. / Dose considerations for anti-cancer drugs in metastatic prostate cancer. In: Prostate. 2017 ; Vol. 77, No. 11. pp. 1199-1204.
@article{2bab7e7021f440d4a5f6523d57dfb990,
title = "Dose considerations for anti-cancer drugs in metastatic prostate cancer",
abstract = "Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.",
keywords = "dosing, prostate cancer, treatment",
author = "Megan Crumbaker and Howard Gurney",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/pros.23378",
language = "English",
volume = "77",
pages = "1199--1204",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss, Wiley",
number = "11",

}

Dose considerations for anti-cancer drugs in metastatic prostate cancer. / Crumbaker, Megan; Gurney, Howard.

In: Prostate, Vol. 77, No. 11, 01.08.2017, p. 1199-1204.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Dose considerations for anti-cancer drugs in metastatic prostate cancer

AU - Crumbaker, Megan

AU - Gurney, Howard

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.

AB - Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.

KW - dosing

KW - prostate cancer

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85021323910&partnerID=8YFLogxK

U2 - 10.1002/pros.23378

DO - 10.1002/pros.23378

M3 - Review article

VL - 77

SP - 1199

EP - 1204

JO - Prostate

T2 - Prostate

JF - Prostate

SN - 0270-4137

IS - 11

ER -